Bevacizumab: Difference between revisions
David Canner (talk | contribs) No edit summary |
No edit summary |
||
| (5 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
< | <StructureSection load='' size='350' side='right' scene='Bevacizumab/Ba/1' caption='Model Bevacizumab, also known as Avastin (PDB code [[1igt]])'> | ||
__TOC__ | |||
===Better Known as: Avastin=== | ===Better Known as: Avastin=== | ||
* Marketed By: Genentech & Roche<br /> | * Marketed By: Genentech & Roche<br /> | ||
| Line 7: | Line 9: | ||
* 2009 Sales: $4.8 Billion | * 2009 Sales: $4.8 Billion | ||
* Importance: It is one of the best selling [[cancer]] treatments in history. Despite being effective against colorectal cancer, post-approval studies after accelerated approval revealed that Avastin was ineffective in treating breast cancer. Many question the $90,000/year bill to take Avastin when it extends life on average only 10 months. | * Importance: It is one of the best selling [[cancer]] treatments in history. Despite being effective against colorectal cancer, post-approval studies after accelerated approval revealed that Avastin was ineffective in treating breast cancer. Many question the $90,000/year bill to take Avastin when it extends life on average only 10 months. | ||
* | * See [[Pharmaceutical Drugs]] for more information about other drugs and disorders | ||
===Mechanism of Action=== | ===Mechanism of Action=== | ||
| Line 15: | Line 17: | ||
{| class="wikitable" border="1" width="30%" style="text-align:center" | {| class="wikitable" border="1" width="30%" style="text-align:center" | ||
|- | |- | ||
! colspan="2" align="center"| VEGF Inhibitor [[ | ! colspan="2" align="center"| VEGF Inhibitor [[Pharmacokinetics]]<ref>PMID:17093010</ref> | ||
|- | |- | ||
! Parameter | ! Parameter | ||
! [[Bevacizumab]] | ! [[Bevacizumab]] | ||
|- | |- | ||
! [[ | ! [[Pharmacokinetics#Tmax|T<sub>max</sub>]] (hr) | ||
! 5.17 | ! 5.17 | ||
|- | |- | ||
! [[ | ! [[Pharmacokinetics#Cmax|C<sub>max</sub>]] (ng/ml) | ||
! 284000 | ! 284000 | ||
|- | |- | ||
! [[ | ! [[Pharmacokinetics#Bioavailability_.28F.29|Bioavailability]] (%) | ||
! 100 | ! 100 | ||
|- | |- | ||
! [[ | ! [[Pharmacokinetics#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (days) | ||
! 20 | ! 20 | ||
|- | |- | ||
! [[ | ! [[Pharmacokinetics#Area_Under_the_Curve_.28AUC.29|AUC]] (ug/ml/hr) | ||
! 97488 | ! 97488 | ||
|- | |- | ||
! [[ | ! [[Pharmacokinetics#Inhibitory_Concentration_.28IC50.29|IC<sub>50</sub>]] (nM) | ||
! .9 | ! .9 | ||
|- | |- | ||
! [[ | ! [[Pharmacokinetics#Clearance_.28Cl.29|Clearance]] (L/h) | ||
! .0096 | ! .0096 | ||
|- | |- | ||
| Line 44: | Line 46: | ||
! 10 | ! 10 | ||
|} | |} | ||
</StructureSection> | |||
===References=== | ===References=== | ||
<references/> | <references/> | ||
__NOEDITSECTION__ | __NOEDITSECTION__ | ||
__NOTOC__ | __NOTOC__ | ||